Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
This article compares expense ratios for SP 500 ETFs and index funds inside a Roth IRA, highlighting how fees affect long-term growth.
28,234 articlesTeva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Mortgage demand dropped sharply in the latest MBA survey, with refinances leading the decline as rates trended higher...
Israel expanded its Lebanon assault, widening ground incursions as Hezbollah escalates strikes. The move rattles mark...
SpaceX has been a marquee name in tech and defense circles. If spacex down from all-time high, investors should analy...
During 13F season, big investors reveal shifts in their portfolios. This piece explains the move, why Microsoft was f...
Is Palantir stock undervalued stock? This in-depth guide breaks down the AI growth case, valuation angles, and how to...
Berkshire Hathaway's Greg Abel could be quietly steering a strategic tilt toward AI-enabled winners. This deep dive e...
A bold claim from a tech titan can set off a market ripple. This article breaks down what elon musk just claimed coul...
XRP slid about 19% over the past week, hitting multi-month lows. A ChatGPT-style AI forecast points to a potential ne...
Have tech stocks finally run out of road? This data-driven exploration breaks down valuations, growth drivers, and ho...
SpaceX has fueled a surge of activity in the AI and tech space. This guide explains what the moves mean for your port...
Alphabet is stepping up its AI game, signaling big potential and bigger risks for investors. This piece breaks down w...